LAEKNA-B (02105) saw its shares rise more than 5% in late trading. As of the time of writing, the stock was up 3.83%, trading at HK$13.82 with a turnover of HK$25.91 million. On April 30, Qilu Pharmaceutical officially announced that the pivotal Ib/III phase clinical study of the innovative targeted drug afuresertib (R&D code: LAE002), for which it holds exclusive rights for development and commercialization in China, in combination with fulvestrant for the treatment of HR+/HER2- advanced breast cancer, has met its primary endpoint. Qilu will proceed with the domestic new drug application. Public information indicates that LAE002 is a potent AKT inhibitor independently developed by LAIKENA. According to the agreement between LAIKENA and Qilu Pharmaceutical, if LAE002 receives approval for its first indication in China, LAIKENA is eligible to receive a non-refundable upfront payment of RMB 530 million and milestone payments totaling up to RMB 2.045 billion. Additionally, LAIKENA is entitled to receive sales royalties based on the future net sales of the drug in China, with royalty rates ranging from over ten percent to over twenty percent.